Biotech and Pharmaceuticals Pharmaceuticals

More

  • Steve Jobs: Can His Case Help Propel Biopharma? Thursday, 15 Jan 2009 | 2:17 PM ET

    Even though it's one of the leading causes of cancer death in the U.S., pancreatic normally doesn't get much attention.

  • Four Hot Stocks in Four Diverse Sectors Thursday, 15 Jan 2009 | 11:47 AM ET

    Paul Noglows, director of research at Lazard Capital Markets, suggested four stock picks in four different sectors that will see growth over the year.

  • Genentech's Quiet Period Times Two Wednesday, 14 Jan 2009 | 10:45 AM ET

    I couldn't go to the formal, scripted Genentech presentation at the JPMorgan Healthcare Conference yesterday afternoon because I was busy doing the crazy interview on "Fast Money" with the CEO of athenahealth, Jonathan Bush. I've never done a CEO interview like it.

  • A Tale Of Two Industries Tuesday, 13 Jan 2009 | 12:25 PM ET
    Jamie Dimon

    During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."

  • Is Roche In A Rush For Genentech? Monday, 12 Jan 2009 | 1:35 PM ET
    Roche CFO's presentation at the JPMorgan Healthcare Conference

    Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference.

  • JPMorgan Conference Feels Wall Street Pinch Monday, 12 Jan 2009 | 11:44 AM ET
    jp_morgan_front.jpg

    I'm covering the 27th Annual JPMorgan Healthcare Conference in San Francisco where I suspect there will be a big crowd for the Roche presentation later this morning. It's being reported that the Swiss drugmaker may soon raise its bid for Genentech. I'll be shocked if Roche says much about it either in the formal presentation or breakout session. But I'll be there just in case.

  • Cramer's Dow Jones All-Stars Friday, 9 Jan 2009 | 12:01 PM ET

    There's a method behind his Mad Money picks. Here's how you put that strategy to work yourself.

  • Ladies In Waiting For Merck's Gardasil Friday, 9 Jan 2009 | 10:08 AM ET

    The FDA giveth and the FDA taketh away. Yesterday the agency handed Merck a little bit of a break with what could be interpreted as an endorsement, of sorts. But then this morning the FDA issued another delay in deciding whether to approve the company's Gardasil vaccine.

  • Hospitals Injure Cardinal Health, Intuitive Surgical Thursday, 8 Jan 2009 | 10:48 AM ET
    intuitive_surgical.jpg

    Within about a 12-hour period, two healthcare companies have blamed the pullback in hospital spending for worse-than-anticipated financial results.

  • Cramer's Top Five Dow Stocks: Johnson & Johnson Wednesday, 7 Jan 2009 | 7:25 PM ET

    That this stock does well during recessions is just one of many reasons it's a Mad Money favorite.

  • Alert The Elanians: A Bull's On The Loose Wednesday, 7 Jan 2009 | 10:51 AM ET
    elan.jpg

    Don't look now, but in the first week of the new year shares of Elan stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec, and efficacy concerns over the Alzheimer's drug it's developing with Wyeth.

  • The NYT, JNJ & That Tricky "Billion" Monday, 5 Jan 2009 | 4:01 PM ET
    JandJ_NYT_ad2.jpg

    We all make mistakes. Gosh knows I've made more than a few. And a part of me hesitates to call attention to this one. I mean, you know what they say about paybacks and karma. But this one is too good a doozy to let pass.

  • Pfizer Rekindling Deal Talk? Monday, 5 Jan 2009 | 11:25 AM ET
    pfizer_hq.jpg

    The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."

  • Glaxo, Merck & Pfizer: Your Emails Tuesday, 23 Dec 2008 | 1:16 PM ET

    As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.

  • Vertex's $75,000 Question Friday, 19 Dec 2008 | 3:14 PM ET

    Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.

  • Obama, Bernanke As Market Catalysts Wednesday, 17 Dec 2008 | 11:17 PM ET

    We finished the day down, but these two guys were responsible for much of the trading session’s strength, Cramer says.

  • Bristol-Myers To Cut Another 10% of Workforce Tuesday, 16 Dec 2008 | 6:02 PM ET
    bristol_myers_squibb.jpg

    Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.

  • Pfizer's 40 Year Run Of Hiking Dividend Ends Tuesday, 16 Dec 2008 | 10:44 AM ET
    pfizer_hq.jpg

    For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.

  • The Pharma Trade Monday, 15 Dec 2008 | 3:45 PM ET
    graphic_fast_money.jpg

    Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?

  • Your Buffett Moment Thursday, 11 Dec 2008 | 6:20 PM ET

    With stocks down substantially in 2008, could next year be the opportunity of a lifetime to get long?